Portfolio
ABOUT:
Khondrion is a clinical stage biopharmaceutical company developing therapies for patients with primary mitochondrial disease (PMD). The company’s lead asset, sonlicromanol, is a potentially first-in-class, brain-penetrant redox-modulator with anti-inflammatory properties, that targets key metabolic and inflammatory pathways underlying PMD.
Learn more at khondrion.com.
ABOUT:
Napigen is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes and animals. The company is developing new gene editing technologies to provide potential cures for mitochondrial diseases.
Learn more at napigen.com.
INVESTMENT:
A $100,000 UMDF research grant
has been converted to equity.
ABOUT:
Pierrepont Therapeutics, Inc. is dedicated to developing targeted treatments for primary mitochondrial and other rare genetic diseases. Pierrepont’s lead product candidate, PTI-501 (formerly ENTR-501) is a proprietary intracellular enzyme replacement therapy for the treatment of MNGIE that is exclusively licensed from Entrada Therapeutics, Inc. (Nasdaq: TRDA).
Learn more at www.PierrepontTx.com.
INVESTMENT:
$500,000
Interested in having
The Mito Fund
explore investment
in your company?
